Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Linaclotide (Linzess) vs Synthetic Secretin (ChiRhoStim)
An educational, source-based comparison of Linaclotide (Linzess) and Synthetic Secretin (ChiRhoStim) — how each peptide works, what it's researched for, and what to know before going deeper.
Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.
- IBS-C
- Chronic idiopathic constipation
- Functional constipation in children
- • FDA-approved.
- • Contraindicated in children <2 years; diarrhea common.
27-amino-acid peptide used to stimulate pancreatic secretions for diagnosis.
Synthetic human secretin that stimulates pancreatic bicarbonate, fluid secretion, and gastrin release — used diagnostically for pancreatic function, gastrinoma evaluation, and ERCP facilitation.
- Pancreatic function testing
- Gastrinoma (Zollinger-Ellison) diagnosis
- ERCP facilitation
- • FDA-approved.
- • Single diagnostic dose; minimal adverse effects.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Linaclotide (Linzess) | Linaclotide phase 3 trials | NEJM | 2011 | Improved abdominal pain and bowel function in IBS-C. |
| Synthetic Secretin (ChiRhoStim) | Secretin stimulation test for gastrinoma | Gastroenterology | 1989 | Established as gold standard provocative test. |
Side-effect & safety grid
- FDA-approved.
- Contraindicated in children <2 years; diarrhea common.
- FDA-approved.
- Single diagnostic dose; minimal adverse effects.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Linaclotide (Linzess) vs Synthetic Secretin (ChiRhoStim) — Key differences
- Class: Linaclotide (Linzess) is classified as GC-C Agonist · Gastrointestinal, while Synthetic Secretin (ChiRhoStim) is Diagnostic · Gastroenterology.
- Primary research focus: Linaclotide (Linzess) — ibs-c; Synthetic Secretin (ChiRhoStim) — pancreatic function testing.
- Tag: FDA-Approved · GI vs FDA-Approved · Diagnostic.